Pasar al contenido principal

MODULACION DE PROTEINA QUINASAS Y BACE-1 CON MOLECULAS PEQUEÑAS DE DISEÑO MULTIDIANA: UNA NUEVA APROXIMACION PARA LA PREVENCION Y TRATAMIENTO DE LAS ENFERMEDADES COGNITIVAS

SAF2016-76693-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2016
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 22
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer's disease

  • Chierrito, Talita P. C.
  • Roca, Carlos
  • Requena-Triguero, Carlos
  • Sebastián-Pérez, Víctor
  • Pérez, Concepción
  • Jiménez-Barbero, Jesús
  • Cañada, F. Javier
  • Campillo, Nuria E.
  • Martínez Gil, Ana
  • Carvalho, Ivone
68 p.-17 fig.-1 tab. Chierrito, Talita P. C. et al., The lack of an effective treatment for Alzheimer' disease (AD), an increasing prevalence and severe neurodegenerative pathology boost medicinal chemists to look for new drugs. Currently, only acethylcholinesterase (AChE) inhibitors and glutamate antagonist have been approved to the palliative treatment of AD. Although they have a short-term symptomatic benefits, their clinical use have revealed important non-cholinergic functions for AChE such its chaperone role in beta-amyloid toxicity. We propose here the design, synthesis and evaluation of non-toxic dual binding site AChEIs by hybridization of indanone and quinoline heterocyclic scaffolds. Unexpectely, we have found a potent allosteric modulator of AChE able to target cholinergic and non-cholinergic functions by fixing a specific AChE conformation, confirmed by STD-NMR and molecular modeling studies. Furthermore the promising biological data obtained on human neuroblastoma SH-SY5Y cell assays for the new allosteric hybrid 14, led us to propose it as a valuable pharmacological tool for the study of non-cholinergic functions of AChE, and as a new important lead for novel disease modifying agents against AD., Financial support of this research provided by the Fundação de Pesquisa e Amparo do Estado de São Paulo-FAPESP (Proc. 12/04054-5; 12/14114-5; 13/50788-3; 14-10414-0); Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), CSIC (grant no. i-LINK-0801) and MINECO (grants no. SAF2016-76693-R to A.M., and CTQ2015-64597-C2-1 to J.J.B. and F.J.C.) is acknowledged, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Recapitulation of pathological TDP-43 features in immortalized lymphocytes from sporadic ALS patients

  • Posa, Diana
  • Martínez-González, Loreto
  • Bartolomé Robledo, Fernando
  • Siranjeevi, Nagaraj
  • Porras, Gracia
  • Martínez Gil, Ana
  • Martín-Requero, Ángeles
31 p.-5 fig.-1 tab., Amyotrophic lateral sclerosis (ALS) is a fatal progressive neurodegenerative disorder of still unknown etiology that results in loss of motoneurons, paralysis, and death, usually between 2 and 4 years from onset. There are no currently available ALS biomarkers to support early diagnosis and to facilitate the assessment of the efficacy of new treatments. Since ALS is considered a multisystemic disease, here we have investigated the usefulness of immortalized lymphocytes from sporadic ALS patients to study TDP-43 homeostasis as well as to provide a convenient platform to evaluate TDP-43 phosphorylation as a novel therapeutic approach for ALS. We report here that lymphoblasts from ALS patients recapitulate the hallmarks of TDP-43 processing in affected motoneurons, such as increased phosphorylation, truncation, and mislocalization of TDP-43. Moreover, modulation of TDP-43 by an in-house designed protein casein kinase-1δ (CK-1δ) inhibitor, IGS3.27, reduced phosphorylation of TDP-43, and normalized the nucleo-cytosol translocation of TDP-43 in ALS lymphoblasts. Therefore, we conclude that lymphoblasts, easily accessible cells, from ALS patients could be a useful model to study pathological features of ALS disease and a suitable platform to test the effects of potential disease-modifying drugs even in a personalized manner., This work has been supported by grants from MINECO (CTQ2015-66313-R to A.M.-R. and SAF2016-76693-R to A.M.) and Madrid Community (B2017/BMD3813 ELA-Madrid)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

High fructose corn syrup consumption in adolescent rats causes bipolar-like behavioural phenotype with hyperexcitability in hippocampal CA3-CA1 synapses, High fructose led to bipolar-like phenotype in adolescent rats

  • Alten, Baris
  • Yesiltepe, Metin
  • Tas, Sadik Taskin
  • Gocmen, Ayse Yesim
  • Kursungoz, Canan
  • Martínez Gil, Ana
  • Sara, Yildirim
39 p.-5 fig.-1 tab., BACKGROUND AND PURPOSE: Children and adolescents are the top consumers of high fructose corn syrup (HFCS) sweetened beverages. Even though the cardiometabolic consequences of HFCS consumption in adolescents are well known, the neuropsychiatric consequences have yet to be determined., EXPERIMENTAL APPROACH: Adolescent rats were fed for a month with 11% weight/volume carbohydrate containing HFCS solution, which is similar to the sugar sweetened beverages of human consumption. The metabolic, behavioural and electrophysiologic characteristics of HFCS-fed rats were determined. Furthermore, the effects of TDZD-8, a highly specific GSK-3 inhibitor, on the HFCS-induced alterations were further explored., KEY RESULTS: HFCS-fed adolescent rats displayed bipolar-like behavioural phenotype with hyperexcitability in hippocampal CA3-CA1 synapses. This hyperexcitability was associated with increased presynaptic release probability and increased readily available pool of AMPA receptors to be incorporated into the postsynaptic membrane, due to decreased expression of the neuron-specific alpha3-subunit of Na+ /K+ -ATPase (NKA) and an increased ser845-phosphorylation of GluR1 subunits of AMPA receptors, respectively. TDZD-8 treatment was found to restore behavioural and electrophysiological disturbances associated with HFCS consumption by inhibition of GSK-3, the most probable mechanism of action of lithium for its mood-stabilizing effects., This study shows that HFCS consumption in adolescent rats led to bipolar‐like behavioural phenotype with neuronal hyperexcitability, which is known to be one of the earliest endophenotypic manifestations of bipolar disorder. Inhibition of GSK‐3 with TDZD‐8 attenuated hyperexcitability and restored HFCS‐induced behavioural alterations., Funding from Hacettepe University Scientific Research Project Coordination Unit (Grant no. TSA-2017-15515 to Yildirim Sara) and partial funding from MINECO (Grant no. SAF2012-37979-C03-01 and SAF2016-76693-R to Ana Martinez) are acknowledged, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases

  • Nozal, Vanesa
  • Martínez Gil, Ana
22 p.-6 fig., Tau-tubuline kinases (TTBK) are a family of serine/threonine and tyrosine kinases recently discovered and implicated in the phosphorylation of important substrates such as tau, tubuline or TDP-43. Its two homologs, TTBK1 and TTBK2, show different expression patterns and different involvements in physiological mechanisms of great importance such as mitosis, ciliogenesis and neurotransmission. Their phosphorylation activity has also linked them to the development of neurodegenerative diseases like Alzheimer’s disease, amyotrophic lateral sclerosis or spinocerebellar ataxia type 11. There are currently only three inhibitors of these kinases described in the literature. This review intends to give an overview of the structure, expression, physiological and pathological mechanisms of both kinases as well as an extended analysis on the molecules that can inhibit them. The final analysis of all this information led us to propose TTBK1 as a new target for the treatment of neurodegenerative diseases and its selective inhibitors as potential effective drugs for the treatment of these severe unmet disorders., This work has been funding by grants from Comunidad de Madrid (B2017/BMD3813 ELA-Madrid) and MINECO (SAF2016-76693-R). V.N. holds a pre-doctoral FPU grant (FPU16/04466)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Computer-aided molecular design of pyrazolotriazines targeting glycogen synthase kinase 3

  • Sciú, María Lourdes
  • Sebastián-Pérez, Víctor
  • Martínez-González, Loreto
  • Benítez, Rocio
  • Pérez, Daniel I.
  • Pérez, Concepción
  • Campillo, Nuria E.
  • Martínez Gil, Ana
  • Moyano, Elizabeth Laura
11 p.-9 fig.-3 tab., Numerous studies have highlighted the implications of the glycogen synthase kinase 3 (GSK-3) in several processes associated with Alzheimer's disease (AD). Therefore, GSK-3 has become a crucial therapeutic target for the treatment of this neurodegenerative disorder. Hereby, we report the design and multistep synthesis of ethyl 4-oxo-pyrazolo[4,3-d][1-3]triazine-7-carboxylates and their biological evaluation as GSK-3 inhibitors. Molecular modelling studies allow us to develop this new scaffold optimising the chemical structure. Potential binding mode determination in the enzyme and the analysis of the key features in the catalytic site are also described. Furthermore, the ability of pyrazolotriazinones to cross the blood-brain barrier (BBB) was evaluated by passive diffusion and those who showed great GSK-3 inhibition and permeation to the central nervous system (CNS) showed neuroprotective properties against tau hyperphosphorylation in a cell-based model. These new brain permeable pyrazolotriazinones may be used for key in vivo studies and may be considered as new leads for further optimisation for the treatment of AD., Funding from MINECO (grant no. SAF2016-76693-R to A.M.) and MEC (FPU15/1465 to VSP.), CONICET and SECYT-UNC are also acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors

  • Chierrito, Talita P. C.
  • Pedersoli-Mantoani, S.
  • Roca, Carlos
  • Sebastián-Pérez, Víctor
  • Martínez-González, Loreto
  • Pérez, Daniel I.
  • Pérez, Concepción
  • Canales, Ángeles
  • Cañada, F. Javier
  • Campillo, Nuria E.
  • Carvalho, Ivone
  • Martínez Gil, Ana
Alzheimer's disease (AD) is the most common form of dementia worldwide with an increasing prevalence for the next years. The multifactorial nature of AD precludes the design of new drugs directed to a single target being probably one of the reasons for recent failures. Therefore, dual binding site acetylcholinesterase (AChE) inhibitors have been revealed as cognitive enhancers and β-amyloid modulators offering an alternative in AD therapy field. Based on the dual ligands NP61 and donepezil, the present study reports the synthesis of a series of indolylpiperidines hybrids to optimize the NP61 structure preserving the indole nucleus, but replacing the tacrine moiety of NP61 by benzyl piperidine core found in donepezil. Surprisingly, this new family of indolylpiperidines derivatives showed very potent and selective hBuChE inhibition. Further studies of NMR and molecular dynamics have showed the capacity of these hybrid molecules to change their bioactive conformation depending on the binding site, being capable to inhibit with different shapes BuChE and residually AChE., Financial support of this research provided by the Fundaç~ao de Pesquisa e Amparo do Estado de S~ao Paulo-FAPESP (Proc.12/04054- 5; 12/14114-5; 13/50788-3; 14/10414-0; 17/04695-4); Coordenaç~ao de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), CSIC (grant no. i-LINK-0801) and MINECO (grants no. SAF2016-76693-R to A.M., CTQ 2016-76263 to A.C. and CTQ 2015- 64597-C2-2 to F.J.C.) is acknowledged. Authors want to express their gratitude to Prof. G. Pepeu for the experimental work in target engagement., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

TDP-43: a key therapeutic target beyond amyotrophic lateral sclerosis

  • Palomo, Valle
  • Tosat-Bitrian, Carlota
  • Nozal, Vanesa
  • Nagaraj, Siranjeevi
  • Martín-Requero, Ángeles
  • Martínez Gil, Ana
48 p.-7 fig.-1 graph. abst., Accumulation of TDP-43 in the cytoplasm of diseased neurons is the pathological hallmark of frontotemporal dementia-TDP (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), two diseases that lack efficacious medicine to prevent or to stop disease progression. The discovery of mutations in the TARDBP gene (encoding the nuclear protein known as TDP-43) in both FTLD and ALS patients provided evidence for a link between TDP-43 alterations and neurodegeneration. Our understanding of TDP-43 function has advanced profoundly in the past several years; however, its complete role and the molecular mechanisms that lead to disease are not fully understood. Here we summarize the recent studies of this protein, its relation to neurodegenerative diseases, and the therapeutic strategies for restoring its homeostasis with small molecules. Finally, we briefly discuss the available cellular and animal models that help to shed light on TDP-43 pathology and could serve as tools for the discovery of pharmacological agents for the treatment of TDP-43-related diseases., Funding from Comunidad de Madrid (B2017/BMD3813 ELA-Madrid), MINECO (SAF2016-76693-R), ISCiii (CIBERNED, CB18/05/00040), and the La Caixa Junior Leader retaining program is acknowledged. V.N. holds a predoctoral FPU grant (FPU16/04466). S.N. was supported by a stipend from the Bio4Med Program (MarieSklodowska-Curie Cofound Grant Agreement 665735)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

1-Aryl-3-(4-methoxybenzyl)ureas as potentially irreversible glycogen synthase kinase 3 inhibitors: Synthesis and biological evaluation

  • Venter, Jana
  • Pérez, Concepción
  • van Otterlo, Willem A. L.
  • Martínez Gil, Ana
  • Blackie, Margaret A.L.
4 p.-4 fig.-1 tab., Glycogen synthase kinase 3 (GSK-3) has become known for its multifactorial involvement in the pathogenesis of Alzheimer’s disease. In this study, a benzothiazole- and benzimidazole set of 1-aryl-3-(4-methoxybenzyl)ureas were synthesised as proposed Cys199-targeted covalent inhibitors of GSK-3β, through the incorporation of an electrophilic warhead onto their ring scaffolds. The nitrile-substituted benzimidazolylurea 2b (IC50 = 0.086 ± 0.023 µM) and halomethylketone-substituted benzimidazolylurea 9b (IC50 = 0.13 ± 0.060 µM) displayed high GSK-3β inhibitory activity, in comparison to reference inhibitor AR-A014418 (1, IC50 = 0.072 ± 0.043) in our assay. The results suggest further investigation of 2b and 9b as potential covalent inhibitors of GSK-3β, since a targeted interaction might provide improved kinase-selectivity., This research was financially supported by the National Research Foundation, South Africa (Innovation Master’s Scholarship 2017–2018), Stellenbosch University and MINECO (Grant No. SAF2016-76693-R)., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Subtly modulating glycogen synthase kinase 3 ß: Allosteric inhibitor development and their potential for the treatment of chronic diseases

  • Palomo, Valle
  • Pérez, Daniel I.
  • Roca, Carlos
  • Anderson, Cara
  • Rodríguez-Muela, Natalia
  • Pérez, Concepción
  • Morales-García, José A.
  • Reyes Rodríguez, Julio Alberto
  • Campillo, Nuria E.
  • Pérez Castillo, Ana
  • Rubin, Lee L.
  • Timchenko, Lubov
  • Gil, Carmen
  • Martínez Gil, Ana
Glycogen synthase kinase 3 ß (GSK-3ß) is a central target in several unmet diseases. To increase the specificity of GSK-3ß inhibitors in chronic treatments, we developed small molecules allowing subtle modulation of GSK-3ß activity. Design synthesis, structure¿activity relationships, and binding mode of quinoline-3-carbohydrazide derivatives as allosteric modulators of GSK-3ß are presented here. Furthermore, we show how allosteric binders may overcome the ß-catenin side effects associated with strong GSK-3ß inhibition. The therapeutic potential of some of these modulators has been tested in human samples from patients with congenital myotonic dystrophy type 1 (CDM1) and spinal muscular atrophy (SMA) patients. We found that compound 53 improves delayed myogenesis in CDM1 myoblasts, while compounds 1 and 53 have neuroprotective properties in SMA-derived cells. These findings suggest that the allosteric modulators of GSK-3ß may be used for future development of drugs for DM1, SMA, and other chronic diseases where GSK-3ß inhibition exhibits therapeutic effects., This work was financially supported by MINECO (grant no. SAF2012-37979-C03-01 and SAF2016-76693-R to A.M. and IJCI-2014-20767 to V.P.). CCHMC funds L.T. A.M. and C.G. are members of the CIB Intramural Program “Molecular Machines for Better Life” (MACBET)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Benzothiazole-based LRRK2 inhibitors as Wnt enhancers and promoters of oligodendrocytic fate

  • Zaldívar-Díez, Josefa
  • Li, Lingling
  • García, Ana M.
  • Zhao, Wenning
  • Medina-Menendez, Cristina
  • Haggarty, Stephen J.
  • Gil, Carmen
  • Morales, Aixa V.
  • Martínez Gil, Ana
63 p.-15 fig.-1 tab.-2 schem., Leucine Rich Repeat Kinase 2 (LRRK2) is an enigmatic enzyme and a relevant target for Parkinson’s Disease (PD). However, despite the significant amount of research done in the last decade, the precise function of LRRK2 remains largely unknown. Moreover, the therapeutic potential of its inhibitors is in its infancy with the first clinical trial having just started. In the present work the molecular mechanism of LRRK2 in the control of neurogenesis or gliogenesis was investigated. We designed and synthesized novel benzothiazole-based LRRK2 inhibitors and showed that they can modulate the Wnt/β-catenin signaling pathway. Furthermore, compounds 5 and 14 were able to promote neural progenitors proliferation and drive their differentiation towards neuronal and oligodendrocytic cell fates. These results suggest potential new avenues for the application of LRRK2 inhibitors in demyelinating diseases in which oligodendrocyte cell-death is one of the pathological features., This work was supported by MINECO (grant SAF2016-76693-R to A.M. and SAF2017-85717-R to A.V.M.), CIBERNED (CB18/05/00040 to A.M.), MECD (FPU13-003262 to J.Z.-D.), CEU-Banco Santander (Scholarships for the Research Mobility Program CEU-BANCO SANTANDER to J.Z.-D.), Fundación Alicia Koplowitz (Research Project, 2018 to A.V.M.) and Tau Consortium and Stuart & Suzanne Steele MGH Research Scholar Award to S.J.H, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Improved linkage design for the discovery of multitarget ligands as powerful drugs for Alzheimer’s disease

  • Nozal, Vanesa
  • García-Rubia, Alfonso
  • Pérez, Concepción
  • Martínez Gil, Ana
  • Palomo, Valle
14 p.-5 fig.-2 tab., [ENG] Multitarget drugs are molecular entities that are designed to present more than one biological activity. They are arising as powerful tools to tackle complex diseases including bacterial resistances, cancer or neurodegenerative diseases. Typically, the rational strategies to design multitarget drugs are linkage, fusion and incorporation or merge. Here we present the creation of a multitarget drug combining active fragments in a way that could inhibit an additional third target with the objective to create powerful modulating agents for neurodegenerative diseases. Multitarget compounds are ideally suited for the treatment of these pathologies due to their unknown etiology,multifactorial pathology and lack of efficient treatments.To achieve this aim we have combined fragments that inhibit kinases involved in the main pathomolecular pathways of Alzheimer’s disease such as tau aggregation, neuroinflammation and decreased neurogenesis, looking for a third action in BACE1,responsible of β-amyloid production. Finally, and after the successful results obtained using this methodology,we have started to implement the in situ click chemistry technique to better select the multitarget compounds using BACE1 as a template., [ESP] Los fármacos multidiana son entidades moleculares diseñadas para presentar más de una actividad biológica. Debido a esta propiedad, estos compuestos son considerados herramientas privilegiadas para el tratamiento de enfermedades complejas como las infecciones bacterianas, el cáncer o las enfermedades neurodegenerativas. Las estrategias de diseño para crear fármacos multidiana han sido típicamente unión, fusión e incorporación. En este trabajo presentamos la creación de compuestos multidiana combinando fragmentos activos de tal manera que puedan inhibir una tercera diana adicional una vez unidos, con el objetivo de crear fármacos prometedores para el tratamiento de enfermedades neurodegenerativas. Este tipo de fármacos multidiana resultan muy apropiados para el tratamiento de estas patologías multifactoriales, de las que a día de hoy se desconoce su etiología y que carecen de tratamientos efectivos. Para conseguir este objetivo hemos combinado fragmentos de moléculas que inhiben quinasas involucradas en los mecanismos patomoleculares principales de la enfermedad de Alzheimer como la agregación de tau, la neuroinflamación y la disminución de la neurogénesis.Además se ha buscado una tercera actividad en la enzima BACE1, responsable patología del β-amiloide en la enfermedad de Alzheimer. Finalmente, y tras los resultados prometedores obtenidos con los fármacos multidiana, hemos comenzado a implementar la técnica de química click in situ para optimizar la selección de inhibidores utilizando la enzima BACE1 como molde de reacción., Este trabajo ha sido financiado por el MINECO (SAF2016-76693-R). V.N. poseee un contrato pre-doctoral FPU (FPU16/04466)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Serum- and glucocorticoid-induced kinase 1, a new therapeutic target for autophagy modulation in chronic diseases

  • Maestro, Inés
  • Boya, Patricia
  • Martínez Gil, Ana
13 p.-5 fig.-1 tab., Introduction: Autophagy, a basic cellular degradation pathway essential for survival, is altered both in aging and in many chronic human diseases, including infections, cancer, heart disease, and neurodegeneration. Identifying new therapeutic targets for the control and modulation of autophagy events is therefore of utmost importance in drug discovery. Serum and glucocorticoid activated kinase 1 (SGK1), known for decades for its role in ion channel modulation, is now known to act as a switch for autophagy homeostasis, and has emerged as a novel and important therapeutic target likely to attract considerable research attention in the coming years., Areas covered: In this general review of SGK1 we describe the kinase’s structure and its roles in physiological and pathological contexts. We also discuss small-molecule modulators of SGK1 activity. These modulators are of particular interest to medicinal chemists and pharmacists seeking to develop more potent and selective drug candidates for SGK1, which, despite its key role in autophagy, remains relatively understudied., Expert opinion: The main future challenges in this area are (i) deciphering the role of SGK1 in selective autophagy processes (e.g. mitophagy, lipophagy, and aggrephagy); (ii) identifying selective allosteric modulators of SGK1 with specific biological functions; and (iii) conducting first-in-man clinical studies., Funding support was provided by European Union (EU) (H2020-MSCA-ITN-2017 (grant no. 765912, DRIVE Driving next generation autophagy researchers towards translation); the Autonomous Community of Madrid (CM) (grant no. BMD-3813 ELA_Madrid); and Spanish Ministry of Research and Science (MCIU) and State Research Agency (AEI) (grant numbers PGC2018-098557-B-I00 to P.B. and SAF2016-76693-R to A.M))., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment

  • Martínez-González, Loreto
  • Rodríguez-Cueto, Carmen
  • Cabezudo, Diego
  • Bartolomé Robledo, Fernando
  • Andrés-Benito, Pol
  • Ferrer, Isidro
  • Gil, Carmen
  • Martín-Requero, Ángeles
  • Fernández-Ruiz, Javier
  • Martínez Gil, Ana
  • De Lago, E.
12 p.-6 fig.-2 tab., Pathogenesis of amyotrophic lateral sclerosis (ALS), a devastating disease where no treatment exists, involves the compartmentalization of the nuclear protein TDP-43 (TAR DNA-binding protein 43) in the cytoplasm which is promoted by its aberrant phosphorylation and others posttranslational modifications. Recently, it was reported that CK-1delta (protein casein kinase-1delta) is able to phosphorylate TDP-43. Here, the preclinical efficacy of a benzothiazole-based CK-1delta inhibitor IGS-2.7, both in a TDP-43 (A315T) transgenic mouse and in a human cell-based model of ALS, is shown. Treatment with IGS-2.7 produces a significant preservation of motor neurons in the anterior horn at lumbar level, a decrease in both astroglial and microglial reactivity in this area, and in TDP-43 phosphorylation in spinal cord samples. Furthermore, the recovery of TDP-43 homeostasis (phosphorylation and localization) in a human-based cell model from ALS patients after treatment with IGS-2.7 is also reported. Moreover, we have shown a trend to increase in CK-1delta mRNA in spinal cord and significantly in frontal cortex of sALS cases. All these data show for the first time the in vivo modulation of TDP-43 toxicity by CK-1delta inhibition with IGS-2.7, which may explain the benefits in the preservation of spinal motor neurons and point to the relevance of CK-1delta inhibitors in a future disease-modifying treatment for ALS., This work was supported by MINECO (grant SAF2015-68580-C2-1-R to E.d.L., J.F.R., and C.R.C., SAF2016-76693-R to A.M. and CTQ2015-66313-R to A.M.R.),CIBERNED (CB06/05/0089 to C.R.C., J.F.R. and E.d.L.and CB18/05/00040 to A.M.R. and A.M.), Madrid Community (grant B2017/BMD3813 ELA-Madrid) and EU structural funds (FSE and FEDER)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

From simple quinoxalines to potent oxazolo[5,4-: F] quinoxaline inhibitors of glycogen-synthase kinase 3 (GSK3)

  • Lassagne, F.
  • Duguépéroux, C.
  • Roca, Carlos
  • Pérez, Concepción
  • Martínez Gil, Ana
  • Baratte, B.
  • Robert, T.
  • Ruchaud, S.
  • Bach, Stéphane
  • Erb, W.
  • Roisnel, T.
  • Mongin, F.
2,7-Disubstituted oxazolo[5,4-f]quinoxalines were synthesized from 6-amino-2-chloroquinoxaline in four steps (iodination at C5, substitution of the chloro group, amidation and copper-catalysed cyclization) affording 28 to 44% overall yields. 2,8-Disubstituted oxazolo[5,4-f]quinoxaline was similarly obtained from 6-amino-3-chloroquinoxaline (39% overall yield). For the synthesis of other oxazolo[5,4-f]quinoxalines, amidation was rather performed before substitution; moreover, time-consuming purification steps were avoided between the amines and the final products (38 to 54% overall yields). Finally, a more efficient method involving merging of the last two steps in a sequential process was developed to access more derivatives (37 to 65% overall yields). Most of the oxazolo[5,4-f]quinoxalines were evaluated for their activity on a panel of protein kinases, and a few 2,8-disubstituted derivatives proved to inhibit GSK3 kinase. While experiments showed an ATP-competitive inhibition on GSK3β, structure-activity relationships allowed us to identify 2-(3-pyridyl)-8-(thiomorpholino)oxazolo[5,4-f]quinoxaline as the most potent inhibitor with an IC value of about 5 nM on GSK3α., We thank the Université de Rennes 1 and the Centre National de la Recherche Scientifique for supporting this research. We acknowledge the support from the Fonds Européen de Développement Régional (FEDER; D8 VENTURE Bruker AXS diffractometer). A. M. acknowledges financial support from Spanish Ministry of Innovation, Science and Universities (MICU, grant no. SAF2016-76693-R) and ISCiii (CIBERNED, grant no. CB18/05/00040). S. B. and S. R. also thank the Cancéropôle Grand Ouest (axis: Natural Sea Products in Cancer Treatment), IBiSA (French Infrastructures en sciences duvivant: biologie, santé et agronomie) and Biogenouest (Western France Life Science and Environment Core Facility Network) for supporting KISSf screening facility. We also thank Aurélie Assicot for her contribution to the study and Ludovic Paquin for the generous gift of secondary amines
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Functionalized aromatic esters of the Amaryllidaceae alkaloid haemanthamine and their in vitro and in silico biological activity connected to Alzheimer’s disease

  • Peřinová, Rozálie
  • Maafi, Negar
  • Korábečný, Jan
  • Kohelová, Eliška
  • De Simone, Angela
  • Al Mamun, Abdullah
  • Hulcová, Daniela
  • Marková, Jana
  • Kučera, Tomáš
  • Jun, Daniel
  • Safratova, Marcela
  • Maříková, Jana
  • Andrisano, Vincenza
  • Jenco, Jaroslav
  • Kuneš, Jiří
  • Martínez Gil, Ana
  • Nováková, Lucie
  • Cahlíková, Lucie
23 p.-6 fig.-1 tab., A novel series of aromatic esters (1a-1m) related to the Amaryllidaceae alkaloid (AA) haemanthamine were designed, synthesized and tested in vitro with particular emphasis on the treatment of neurodegenerative diseases. Some of the synthesized compounds revealed promising acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory profile. Significant human AChE (hAChE) inhibition was demonstrated by 11-O-(3-nitrobenzoyl)haemanthamine (1j) with IC50value of 4.0 ± 0.3 µM. The strongest human BuChE (hBuChE) inhibition generated 1-O-(2-methoxybenzoyl)haemanthamine (1g) with IC50 value 3.3 ± 0.4 µM. Moreover, 11-O-(2-chlorbenzoyl)haemanthamine (1m) was able to inhibit both enzymes in dose-dependent manner. The mode of hAChE and hBuChE inhibition was minutely inspected using enzyme kinetic analysis in tandem with in silico experiments, the latter elucidating crucial interaction in 1j-, 1m-hAChE and 1g-, 1m-hBuChE complexes. The blood–brain barrier (BBB) permeability was investigated applying the parallel artificial membrane permeation assay (PAMPA) to predict the CNS availability of the compounds., This project was supported by Charles University grants (GA UK Nr. 178518, SVV UK 260412, 260 401; Progres/UK Q40 and Q42), by MH CZ - DRO (University Hospital Hradec Kralove, Nr. 00179906), by Long-term development plan (Faculty of Military Health Sciences), and by EFSA-CDN (Nr.CZ.02.1.01/0.0/0.0/16_019/0000841) co-funded by ERDF, by MICU (grant Nr. SAF2016-76693-R to A.M.), and by Czech Science Foundation (Nr. 20-29633 J). Computational resources were provided by the CESNET LM2015042 and the CERIT Scientific Cloud LM2015085, provided under the program “Projects of Large Research,Development, and Innovations Infrastructures”., Peer reviewed, preprint
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Therapeutic potential of novel cell division cycle kinase 7 inhibitors on TDP-43-related pathogenesis such as frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS), Running Title: CDC-7 inhibitors correct TDP-43 pathology in ALS and FLTD

  • Vaca, Gabriela
  • Martínez-González, Loreto
  • Fernández, Ana
  • Rojas-Prats, Elisa
  • Porras, Gracia
  • Cuevas, Eva P.
  • Gil, Carmen
  • Martínez Gil, Ana
  • Martín-Requero, Ángeles
38 p.-7 fig.-2 tab., TDP-43 has been identified as the major component of protein aggregates found in affected neurons in FTLD-TDP and ALS patients. TDP-43 is hyperphosphorylated,ubiquitinated and cleaved in the C-terminus. CDC-7 was reported to phosphorylate TDP-43. There are not effective treatments for either FTLD-TDP or ALS, being a pressing need the search of new therapies. We hypothesized that modulating CDC-7 activity with small molecules able to interfere with TDP-43 phosphorylation could be a good therapeutic strategy for these diseases. Here, we have studied the effects of novel brain penetrant, thiopurine-based, CDC-7 inhibitors in TDP-43 homeostasis in immortalized lymphocytes from FTLD-TDP patients, carriers of a loss-of-function GRN mutation, as well as in cells derived from sporadic ALS patients. We found that selective CDC-7 inhibitors, ERP1.14a and ERP1.28a are able to decrease the enhanced TDP-43 phosphorylation in cells derived from FTLD-TDP and ALS patients and to prevent cytosolic accumulation of TDP-43. Moreover, treatment of FTLD-TDP lymphoblasts with CDC-7 inhibitors leads to recovering the nuclear function of TDP43-inducing CDK6 repression. We suggest that CDC-7 inhibitors, mainly the heterocyclic compounds here shown, may be considered as promising drugs candidates for the ALS/FTD spectrum., This work has been supported by grants from Comunidad de Madrid (ELA_Madrid grant B2017/BMD-3813), from the Ministerio de Ciencia, Innovación y Universidades (SAF2016-76693-R to A.M), and ISCiii CIBERNED (CB18/05/00040). G.V. was supported by a fellowship from SENECYT (Ecuador). E.R. was supported by FPU14- 00204 (Ministerio de Educación, Ciencia y Deporte)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis

  • Rojas-Prats, Elisa
  • Martínez-González, Loreto
  • Gonzalo-Consuegra, Claudia
  • Liachko, Nicole F.
  • Pérez, Concepción
  • Ramírez, David
  • Kraemer, Brian C.
  • Martín-Requero, Ángeles
  • Pérez, Daniel I.
  • Gil, Carmen
  • De Lago, E.
  • Martínez Gil, Ana
58 p.-11 fig.-2 tab., Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with no known cure. Aggregates of the nuclear protein TDP-43 have been recognized as a hallmark of proteinopathy in both familial and sporadic cases of ALS. Post-translational modifications of this protein, include hyperphosphorylation, cause disruption of TDP-43 homeostasis and as a consequence, promotion of its neurotoxicity. Among the kinases involved in these changes, cell division cycle kinase 7 (CDC7) plays an important role by directly phosphorylating TDP-43. In the present manuscript the discovery, synthesis, and optimization of a new family of selective and ATP-competitive CDC7 inhibitors based on 6-mercaptopurine scaffold are described. Moreover, we demonstrate the ability of these inhibitors to reduce TDP-43 phosphorylation in both cell cultures and transgenic animal models such as C. elegans and Prp-hTDP43 (A315T) mice. Altogether, the compounds described here may be useful as versatile tools to explore the role of CDC7 in TDP-43 phosphorylation and also as new drug candidates for the future development of ALS therapies., This work was supported by Comunidad de Madrid (grant B2017/BMD-3813), MINECO (grant SAF2016-76693-R and PID2019-105600RB-I00 to A.M., RTI2018-0988885-B-I00 to E.dL. and CTQ2015-66313-R to A.M.R.), ISCii CIBERNED (CB18/05/00040 to A.M., C.G. and A.M.R, and CB06/05/0089 to E.dL.), MECD (FPU14-00204. to E.R.), the National Institutes of Health (R01NS064131 to B.C.K.) and the Department of Veterans Affairs (Merit Review Grants I01BX003755 to B.C.K. and I01BX004044 to N.F.L.), CONICYT-PCI (grant REDES190074 to D.R. and A.M.) and FONDECYT (grant no. 11180604 to D.R.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

From kinase inhibitors to multitarget ligands as powerful drug leads for Alzheimer’s disease using protein-templated synthesis

  • Martínez Gil, Ana
  • Nozal, Vanesa
  • García-Rubia, Alfonso
  • Cuevas, Eva P.
  • Pérez, Concepción
  • Palomo, Valle
  • Tosat-Bitrian, Carlota
  • Bartolomé Robledo, Fernando
  • Carro, Eva
  • Ramírez, David
12 p.-12 fig.-3 tab.-5 schem., Multitarget directed ligands (MTDLs) are arising as promising tools to tackle complex diseases. The main goal of this work is to create powerful modulating agents for neurodegenerative disorders. To achieve this aim, we have combined fragments that inhibit key protein kinases involved in the main pathomolecular pathways of Alzheimer’s disease (AD) such as tau aggregation, neuroinflammation and decreased neurogenesis, whilst looking for a third action in beta-secretase (BACE1), responsible of β-amyloid production. We obtained well-balanced MTDLs with in vitro activity in three different relevant targets and efficacy in two cellular models of AD. Furthermore, computational studies confirmed how these compounds accommodate adequately into the long and rather narrow BACE1 catalytic site. Finally, we employed in situ click chemistry using BACE1 as protein template as a versatile synthetic tool that allowed us to obtain further MTDLs., This work was supported by MINECO (grant SAF2016-76693-R and PID2019-105600RB-I00 to A.M.), ISCiii_CIBERNED (CB18/05/00040 to A.M and A.G.-R., and CB07/502 to E.C. and F.B.), ISCiii_FIS (grant PI18/00118 to E.C.), MECD (FPU16- 04466 to V.N., and FPU18-06310 to C.T.B.), CONICYT-PCI (grant REDES190074 to D.R. and A.M.) and FONDECYT (grant no. 11180604 to D.R.). V.P. has received financial support through the Postdoctoral Junior Leader Fellowship Program (LCF/BQ/PR18/11640007) from “la Caixa” Banking Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Small molecule inhibitors of mammalian GSK-3β promote in vitro plant cell reprogramming and somatic embryogenesis in crop and forest species

  • Berenguer, Eduardo
  • Carneros, Elena
  • Pérez-Pérez, Yolanda
  • Gil, Carmen
  • Martínez Gil, Ana
  • Testillano, Pilar S.
18 p.-10 fig., Plant in vitro regeneration systems, like somatic embryogenesis, are essential in breeding; they permit to propagate elite genotypes, to produce doubled-haploids, and to convert gene editing or transformation events into plants. However, in many crop and forest species somatic embryogenesis is highly inefficient. We report a new strategy to improve in vitro embryogenesis using synthetic small molecule inhibitors of mammalian glycogen synthase kinase 3β (GSK-3β), never used in plants. These inhibitors increased in vitro embryo production in three different systems and species, microspore embryogenesis of Brassica napus and Hordeum vulgare, and somatic embryogenesis of Quercus suber. TDZD-8, representative compound of the molecules tested, inhibited GSK-3 activity in microspore cultures, and increased expression of embryogenesis- genes FUS3, LEC2 and AGL15. Plant GSK-3 kinase BIN2 is master regulator of brassinosteroid (BR) signalling. During microspore embryogenesis, BR biosynthesis and signalling genes CPD, GSK-3-BIN2, BES1 and BZR1 were upregulated and BAS1 catabolic gene was repressed, indicating activation of BR pathway. TDZD-8 increased expression of BR signalling elements, mimicking BR effects. The findings support that the small molecule inhibitors promoted somatic embryogenesis by activating the BR pathway, opening the way for new strategies using GSK-3β inhibitors that could be extended to other species., Work supported by the Spanish National Agency of Research (Agencia Estatal de Investigación, AEI) and European Regional Development Fund (ERDF/FEDER) [grants AGL2017-82447-R and PID2020-113018RB-I00 to PST; and SAF2016-76693-R and PID2019-105600RB-I00 to AM], Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

TDP-43 modulation by Tau-Tubulin kinase 1 inhibitors: A new avenue for future amyotrophic lateral sclerosis therapy

  • Nozal, Vanesa
  • Martínez-González, Loreto
  • Gómez-Almería, Marta
  • Gonzalo-Consuegra, Claudia
  • Santana, Paula
  • Chaikuad, Apirat
  • Cuevas, Eva P.
  • Knapp, Stefan
  • Lietha, Daniel
  • Ramírez, David
  • Petralla, Sabrina
  • Monti, B.
  • Gil, Carmen
  • Martín-Requero, Ángeles
  • Palomo, Valle
  • De Lago, E.
  • Martínez Gil, Ana
68 p.-16 fig.-4 tab.+8 fig. supl.-5 tab. supl., Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease without any effective treatment. Protein TDP-43 is a pathological hallmark of ALS in both sporadic and familiar patients. Post-translational modifications of TDP-43 promote its aggregation in the cytoplasm. Tau-Tubulin kinase (TTBK1) phosphorylates TDP-43 in cellular and animal models; thus, TTBK1 inhibitors emerge as a promising therapeutic strategy for ALS. The design, synthesis, biological evaluation, kinase–ligand complex structure determination, and molecular modeling studies confirmed novel pyrrolopyrimidine derivatives as valuable inhibitors for further development. Moreover, compound 29 revealed good brain penetration in vivo and was able to reduce TDP-43 phosphorylation not only in cell cultures but also in the spinal cord of transgenic TDP-43 mice. A shift to M2 anti-inflammatory microglia was also demonstrated in vivo. Both these activities led to motor neuron preservation in mice, proposing pyrrolopyrimidine 29 as a valuable lead compound for future ALS therapy., This work was supported by Comunidad de Madrid (grant B2017/BMD-3813), the European Social Fund+ (ESF+), MINECO (Grants SAF2016-76693-R to A.M., RTI2018-0988885-B-I00 to E.d.L., and CTQ2015-66313-R to A.M.R.), AIE (RTI2018-099318-B-I00 to D.L., cofunded by the European Regional Development Fund (FEDER)), ISCiii CIBERNED (CB18/05/00040 to A.M., V.P., and A.M.R. and CB06/05/0089 to E.dL.), MECD (FPU16/04466 to V.N.), Cost Action CA15135 “MuTaLig” (COST-STSM-CA15135-37514 to L.M.G.), FONDECYT (Grant 11180604 to D.R.). V.P. has received financial support through the Postdoctoral Junior Leader Fellowship Program (LCF/BQ/PR18/11640007) from “la Caixa” Banking Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Increasing brain permeability of PHA-767491, a cell division cycle 7 kinase inhibitor, with biodegradable polymeric nanoparticles

  • Rojas-Prats, Elisa
  • Tosat-Bitrian, Carlota
  • Martínez-González, Loreto
  • Nozal, Vanesa
  • Pérez, Daniel I.
  • Martínez Gil, Ana
15 p.-8 fig.-2 tab., A potent cell division cycle 7 (CDC7) kinase inhibitor, known as PHA-767491, has been described to reduce the transactive response DNA binding protein of 43 KDa (TDP-43) phosphorylation in vitro and in vivo, which is one of the main proteins found to aggregate and accumulate in the cytoplasm of motoneurons in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) patients. However, the main drawback of this compound is its low permeability to the central nervous system (CNS), limiting its use for the treatment of neurological conditions. In this context, the use of drug delivery systems like nanocarriers has become an interesting approach to improve drug release to the CNS. In this study, we prepared and characterized biodegradable nanoparticles in order to encapsulate PHA-767491 and improve its permeability to the CNS. Our results demonstrate that poly (lactic-co-glycolic acid) (PLGA) nanoparticles with an average radius between 145 and 155 nm could be used to entrap PHA-767491 and enhance the permeability of this compound through the blood–brain barrier (BBB), becoming a promising candidate for the treatment of TDP-43 proteinopathies such as ALS., This research was funded by Comunidad de Madrid (grant B2017/BMD-3813), ISCiii CIBERNED (CB18/05/00040), MINECO (grant SAF2016-76693-R and PID2019-105600RB-I00), and MECD (FPU14-00204 to E.R.P., FPU16-04466 to V.N., and FPU18-06310 to C.T.B.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Rapid discovery and crystallography study of highly potent and selective butylcholinesterase inhibitors based on oxime-containing libraries and conformational restriction strategies

  • Jing, Lanlan
  • Wei, Wenxiu
  • Meng, Bairu
  • Chantegreil, Fabien
  • Nachon, Florian
  • Martínez Gil, Ana
  • Wu, Gaochan
  • Zhao, Huajun
  • Song, Yuning
  • Kang, Dongwei
  • Brazzolotto, Xavier
  • Zhan, Peng
  • Liu, Xinyong
22 p.-9 fig.-8 tab., Butyrylcholinesterase is regarded as a promising drug target in advanced Alzheimer’s disease. In order to identify highly selective and potent BuChE inhibitors, a 53-membered compound library was constructed via the oxime-based tethering approach based on microscale synthesis. Although A2Q17 and A3Q12 exhibited higher BuChE selectivity versus acetylcholinesterase, the inhibitory activities were unsatisfactory and A3Q12 did not inhibit Aβ1-42 peptide self-induced aggregation. With A2Q17 and A3Q12 as leads, a novel series of tacrine derivatives with nitrogen-containing heterocycles were designed based on conformation restriction strategy. The results demonstrated that 39 (IC50 = 3.49 nM) and 43 (IC50 = 7.44 nM) yielded much improved hBuChE inhibitory activity compared to the lead A3Q12 (IC50 = 63 nM). Besides, the selectivity indexes (SI = AChE IC50 / BChE IC50) of 39 (SI = 33) and 43 (SI = 20) were also higher than A3Q12 (SI = 14). The results of the kinetic study showed that 39 and 43 exhibited a mixed-type inhibition against eqBuChE with respective Ki values of 1.715 nM and 0.781 nM. And 39 and 43 could inhibit Aβ1-42 peptide self-induced aggregation into fibril. X-ray crystallography structures of 39 or 43 complexes with BuChE revealed the molecular basis for their high potency. Thus, 39 and 43 are deserve for further study to develop potential drug candidates for the treatment of Alzheimer’s disease., We gratefully acknowledge financial support from the Shandong Provincial Key Research and Development Project (No. 2019JZZY021011), Science Foundation for Outstanding Young Scholars of Shandong Province (ZR2020JQ31), Foreign Cultural and Educational Experts Project (GXL20200015001), Qilu Young Scholars Program of Shandong University, Distinguished Young and Middle-aged Scholar of Shandong University, the Taishan Scholar Program at Shandong Province, and MINECO (Grants SAF2016-76693-R to A.M), F.C., F.N. and X.B. were supported by the French Ministry of Armed Forces (Direction Générale de l'Armement and Service de Santé des Armées, NBC-5-C-4210). Authors would like to thank the ESRF for long-term beamtime access (MX2329 IBS BAG)., Peer reviewed